{
    "clinical_study": {
        "@rank": "164791", 
        "arm_group": [
            {
                "arm_group_label": "LY3025876", 
                "arm_group_type": "Experimental", 
                "description": "Part A:  Escalating doses (0.5 milligram [mg] up to 20 mg) of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Part B:  Placebo matching LY3025876 administered as QD SQ injections for up to 28 days"
            }, 
            {
                "arm_group_label": "LY3025876 + Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "Part B:  LY3025876 (dose will be determined by Part A) and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks."
            }, 
            {
                "arm_group_label": "Placebo + Liraglutide", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to assess the safety and tolerability of LY3025876 given\n      alone (Part A) and in combination with liraglutide (Part B) in participants with type 2\n      diabetes mellitus (T2DM)."
        }, 
        "brief_title": "A Study of LY3025876 in Participants With Diabetes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will also evaluate how much of the study drug enters the blood stream and how\n      long it takes for the body to remove the study drug. Information about any side effects that\n      may occur will also be collected. Participants will continue their usual diet and exercise\n      program and may remain on their physician-prescribed dose of metformin.\n\n      Each part of the study is expected to last 10 to 12 weeks on average, not including\n      screening. Participants may only enroll in one part."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of type 2 diabetes mellitus (T2DM) as determined by the investigator,\n             controlled with diet or exercise alone or on a stable dose of metformin for at least\n             30 days\n\n          -  Have a body mass index (BMI) greater than or equal to 23 and less than or equal to 45\n             kilograms per square meter (kg/m^2) at screening\n\n          -  Have a supine blood pressure reading at screening of between 90-160 millimeter of\n             mercury (mmHg) (systolic) and 40-95 mmHg (diastolic)\n\n          -  Women not of child-bearing potential due to surgical sterilization (hysterectomy or\n             bilateral oophorectomy or tubal ligation) or menopause\n\n        Exclusion Criteria:\n\n          -  Have taken LY3025876 or investigational drugs like it (for example, other fibroblast\n             growth factor-21 [FGF21]-related drugs) or have known allergies to these drugs\n\n          -  History or presence of bone disease (including osteoporosis or unhealed fractures)\n\n          -  Current active treatment of periodontal disease\n\n          -  Have had a significant change in weight, defined as a gain or loss of at least 4\n             kilogram (kg) (9 pounds) in the last 3 months\n\n          -  Have had greater than 1 episode of severe hypoglycemia within 6 months of screening\n             that required the assistance of another person to actively administer carbohydrate,\n             glucagon, or other resuscitative actions or had a seizure or coma\n\n          -  Have known allergies or a history of intolerance to liraglutide, glucagon-like\n             peptide 1 (GLP-1) analogues, or other related compounds\n\n          -  Have a history of acute or chronic pancreatitis\n\n          -  Have a personal or family history of medullary thyroid carcinoma or have multiple\n             endocrine neoplasia syndrome type 2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870297", 
            "org_study_id": "14347", 
            "secondary_id": "I6D-MC-SMRB"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY3025876", 
                    "LY3025876 + Liraglutide"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "LY3025876", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Placebo + Liraglutide"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LY3025876 + Liraglutide", 
                    "Placebo + Liraglutide"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45227"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3025876 in Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Predose on Day 1 up to Day 56 in each Part"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area under the Concentration Curve (AUC) of LY3025876", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 up to 28 days after the first administration of study drug in each Part"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3025876", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 up to 28 days after the first administration of study drug in each Part"
            }, 
            {
                "measure": "Part A:  Immunogenicity: The Number of Participants with Anti-LY3025876 Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Predose on Day 1 through Day 56"
            }, 
            {
                "measure": "Pharmacodynamics (PD): Change from Baseline to Day 28 in Fasting Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 28"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}